Edaravone D5
| Product Name | Edaravone D5 |
|---|---|
| Alternate Names | Edaravone Stable Isotopes, Stable Isotopes of Edaravone |
| CAT No. | CS-Y-00158 |
| CAS No. | 1228765-67-0 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 179.23 g/mol |
| Mol. For. | C₁₀H₅D₅N₂O |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Edaravone |
| Purity | Not less than 90 % |
| Smileys | O=C1N(C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])N=C(C)C1 |
| Canonical Smiles | CC1=NN(C(=O)C1)C2=CC=CC=C2 |
| InchIKey | QELUYTUMUWHWMC-VIQYUKPQSA-N |
| Inchl | InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3/i2D,3D,4D,5D,6D |
| IUPAC | 5-methyl-2-(2,3,4,5,6-pentadeuteriophenyl)-4H-pyrazol-3-one |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Edaravone D5 is a medication that has been used to treat patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. It is a derivative of edaravone, which is a potent antioxidant that is used to treat acute ischemic stroke in Japan. The D5 variant is labeled for research purposes only, and is not intended for human consumption.
The chemical structure of edaravone D5 is similar to that of edaravone, with the difference being the presence of five deuterium atoms. Deuterium is a stable isotope of hydrogen, and the use of deuterium in drug development has been gaining popularity due to the increased stability and prolonged half-life of deuterated compounds.
Edaravone D5 has been used in preclinical studies to investigate the pharmacokinetics and pharmacodynamics of edaravone. It is typically administered intravenously and has been shown to have a longer half-life than edaravone. This prolonged half-life may result in a longer therapeutic effect, which could be beneficial for patients with ALS or other neurodegenerative diseases.
In summary, edaravone D5 is a deuterated variant of edaravone that has been used in preclinical studies to investigate the pharmacokinetics and pharmacodynamics of edaravone. While it is not intended for human consumption, its use in research may lead to the development of more effective treatments for ALS and other neurodegenerative diseases.
Get an Instant Quote
Related Compounds
Edaravone Sulfate Triethylamine SaltD5 | Edaravone Sulfate-D5 | Edaravone-D5 Glucuronide Sodium Salt | Edaravone Glucuronide-D5 |